Home > Insider Trading > Filing (0000950170-25-046943)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1936258	Newamsterdam Pharma Co N.v.	NAMS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1699022	F Douglas Kling	C/O Newamsterdam Pharma Company N.v. Gooimeer 2-35 Naarden P7 1411 DC	Chief Operating Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2025-03-26	16,539	$0.00	60,539	No	4	M	Direct
Ordinary Shares	Disposition	2025-03-26	16,539	$0.00	44,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Restricted Stock Unit	Acquisiton	2025-03-26	16,539	$0.00	16,539	$0.00
Ordinary Shares	Restricted Stock Unit	Disposition	2025-03-26	16,539	$0.00	16,539	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
16,539			No	4	A	Direct
0			No	4	M	Direct

Footnotes

These shares were sold in multiple transactions at a price ranging from $22.75 to $23.20 per share. A portion of the ordinary shares were sold to satisfy tax withholding obligations arising upon the vesting of the restricted stock units ("RSUs"). The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Comission, upon request, full information regarding the number of shares sold in each transaction.
Each RSU represents a contingent right to receive one ordinary share.
Upon grant, all of the RSUs were fully-vested.
The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.